Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study

被引：0
|
作者：
Ma, Xinran [1 ]
Li, Ling [1 ]
Zhang, Lei [1 ]
Li, Xin [1 ]
Fu, Xiaorui [1 ]
Wang, Xinhua [1 ]
Wu, Jingjing [1 ]
Zhang, Xudong [1 ]
Feng, Xiaoyan [1 ]
Zhou, Zhiyuan [1 ]
Chang, Yu [1 ]
Li, Zhaoming [1 ]
Young, Ken H. [2 ]
Zhang, Mingzhi [1 ]
机构：
[1] Zhengzhou Univ, Dept Oncol, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-127912
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2873
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial
    Kalakonda, Nagesh
    Maerevoet, Marie
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Hamad, Nada
    Zijlstra, Josee M.
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Manuel Sancho, Juan
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros P.
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Chang, Hua
    Landesman, Yosef
    Joshi, Anita
    Wang, Hongwei
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael
    Van den Neste, Eric
    Canales, Miguel A.
    LANCET HAEMATOLOGY, 2020, 7 (07): : E509 - E522
  • [22] Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
    Salles, Gilles
    Duell, Johannes
    Gonzalez Barca, Eva
    Tournilhac, Olivier
    Jurczak, Wojciech
    Liberati, Anna Marina
    Nagy, Zsolt
    Obr, Ales
    Gaidano, Gianluca
    Andre, Marc
    Kalakonda, Nagesh
    Dreyling, Martin
    Weirather, Johannes
    Dirnberger-Hertweck, Maren
    Ambarkhane, Sumeet
    Fingerle-Rowson, Gunter
    Maddocks, Kami
    LANCET ONCOLOGY, 2020, 21 (07): : 978 - 988
  • [23] A prospective, open-label, single-arm study to evaluate the efficacy of dydrogesterone in the treatment of endometrial polyps
    Chen, Qian
    Zhang, Da
    Wang, Shu
    Lang, Jing-He
    Chao, Xiao-Pei
    Fan, Qing-Bo
    GYNECOLOGICAL ENDOCRINOLOGY, 2021, 37 (02) : 152 - 156
  • [24] A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; Prelininary results.
    Richardson, P
    Jagannath, S
    Hussein, M
    Berenson, J
    Singhal, S
    Irwin, D
    Williams, SF
    Bensinger, W
    Badros, AZ
    Vescio, R
    Kenvin, L
    Yu, ZN
    Olesnyckyj, M
    Faleck, H
    Zeldis, J
    Knight, R
    Anderson, KC
    BLOOD, 2005, 106 (11) : 449A - 449A
  • [25] Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study
    You, Liangshun
    Liu, Yi
    Mai, Wenyuan
    Xie, Wanzhuo
    Zhou, De
    Mao, Liping
    Chen, Lili
    Zhou, Xinping
    Ma, Liya
    Zheng, Xiaolong
    Wei, Juying
    Lou, Yinjun
    Ye, Xingnong
    Tong, Hongyan
    Jin, Jie
    Meng, Haitao
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [26] Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
    Deng, Li-Juan
    Zhou, Ke-Shu
    Liu, Li-Hong
    Zhang, Ming-Zhi
    Li, Zhi-Ming
    Ji, Chun-Yan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Su-Jun
    Zhang, Hui-Lai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Hai-Yan
    Cao, Jun-Ning
    Zhu, Zun-Min
    Hu, Jian-Da
    Zhang, Wei
    Jing, Hong-Mei
    Ding, Kai-Yang
    Zhang, Xiang-Yang
    Zhao, Ren -Bin
    Zhang, Bin
    Tian, Ya -Min
    Song, Yong-Ping
    Song, Yu-Qin
    Zhu, Jun
    BLOOD ADVANCES, 2023, 7 (16) : 4349 - 4357
  • [27] Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations
    Landsburg, Daniel J.
    Ramchandren, Radhakrishnan
    Hafeez, Amir
    Gharavi, Robert
    Chander, Tania
    Ma, Anna
    Burch, Micah M.
    Oki, Yasuhiro
    BLOOD, 2016, 128 (22)
  • [28] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
    Zhang, Yi
    Zhang, Qike
    Liu, Qingchi
    Dang, Huibing
    Gao, Sujun
    Wang, Wei
    Zhou, Hu
    Chen, Yuqing
    Ma, Liangming
    Wang, Jishi
    Yang, Haiping
    Lu, Binhua
    Yin, Hewen
    Wu, Liqing
    Suo, Shanshan
    Zhao, Qingwei
    Tong, Hongyan
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : 1579 - 1587
  • [29] Efficacy and safety of venetoclax in combination with cytarabine and azacitidine (VAA) in relapsed/refractory acute myeloid leukemia: An open-label, single-arm, phase II study.
    You, Liangshun
    Liu, Yi
    Mai, Wenyuan
    Zhou, De
    Xie, Wanzhuo
    Mao, Liping
    Zhou, Xinping
    Tong, Hongyan
    Jin, Jie
    Meng, Haitao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer
    Li, G.
    Zhao, Y.
    Jiang, Y.
    Yang, Q.
    Huang, A.
    Chen, Y.
    Han, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S753 - S754
12345